The Lancet APC and Open Access: Publication Costs, Elsevier Deals, and Funder Compliance

For the hybrid Lancet titles (including the flagship), the subscription track costs authors nothing. Your paper appears in The Lancet with full indexing, full citation tracking, and the same editorial treatment. The only difference is access: subscription-track papers are behind the paywall for the first 12 months, after which some become freely available.

Most Lancet papers have historically been published via subscription. The shift toward OA is accelerating but not yet dominant for the flagship.

For the gold OA titles (Lancet Global Health, Lancet Public Health, etc.), there is no subscription option. Every article is OA, and every article incurs the $7,860 APC. If you can't pay, you need a waiver.

Like Cell Press, Lancet titles are excluded from most Elsevier Read & Publish agreements. This is a consistent source of frustration for researchers.

Elsevier's standard transformative agreements cover 1,800+ "core hybrid journals." Lancet, Cell Press, and Clinics titles are carved out. The rationale, according to Elsevier, is that these premium brands have different pricing structures.

What this means for you:

• If your university has an Elsevier deal, your APC for a paper in The Lancet is probably NOT covered.
• A few institutions have negotiated expanded agreements that include Lancet titles. The University of California system is the most prominent example, with UCLA Library covering the first $1,000 of the APC and providing a 10% discount.
• UK universities (under the Jisc-Elsevier agreement) have some Lancet coverage, but terms vary and the agreement structure has shifted.

Bottom line: Don't assume your Elsevier institutional deal covers The Lancet. Call your library and ask specifically about Lancet titles before committing to OA.

The Lancet's approach to waivers is more accommodating than some publishers, partly because of its global health mission:

For gold OA Lancet journals:

• Eight gold OA Lancet journals participate in Elsevier's Geographical Pricing for Open Access (GPOA). Authors from lower-income countries receive reduced APCs, sometimes to $0.
• GPOA applies to papers accepted after October 2025 and calculates a personalized price during the production workflow.

For all Lancet journals:

• After acceptance, if you can't pay the full APC and don't have institutional or funder support, The Lancet invites you to contact them.
• You'll need to explain: what funder(s) support your research, what routes you've explored for APC funding, and how much you're able to pay.
• The Lancet states it will apply discounts and waivers based on this information. This is not automatic and requires a conversation, but the journal has a track record of supporting authors from under-resourced settings.

For The Lancet Global Health specifically:

• This journal has been particularly responsive to waiver requests, consistent with its mission to publish research from and about low- and middle-income countries.

The Lancet supports CC BY and CC BY-NC-ND licenses. Plan S requires CC BY. Make sure you select the right license if your funder is a cOAlition S member.

For NIH-funded research: The Lancet allows deposit of accepted manuscripts in PubMed Central after a 12-month embargo. If immediate OA isn't required, the subscription track plus PMC deposit satisfies NIH policy at no cost.

No page fees or color charges. The APC (if you choose OA) is the only publication cost.

Tax applies. EU-based authors and institutions will see VAT added to the APC. This can add 20%+ to the listed price.

Lancet editorial process is long. If you're budgeting APC costs against a grant timeline, note that Lancet review cycles can stretch 6-12 months. The APC is due at acceptance, not submission. Make sure your grant will still be active when the payment comes due.

Commissioning changes the dynamic. The Lancet increasingly commissions content (Reviews, Commissions, Series). Commissioned content may have different APC arrangements or no APC at all. If you're invited to write, ask about costs before agreeing.

Resubmission from another Lancet title. If your paper is rejected from The Lancet flagship and you're invited to transfer to Lancet Oncology or another Lancet title, the APC at the new journal may differ. Transfer does not lock in a price.

For the flagship Lancet:

1. Publish for free via subscription if your funder allows a 12-month embargo. Deposit in PMC after the embargo to satisfy NIH, UKRI (via rights retention), or other green OA mandates.
2. Pay ~$6,500 for gold OA if your funder requires immediate access. Check first: does your institution have a Lancet-specific agreement with Elsevier? If not, can your grant cover it?
3. Contact The Lancet if you need a waiver. They're more receptive than many publishers, especially for researchers from lower-income settings.

For Lancet gold OA journals (Global Health, Public Health, etc.):

The $7,860 APC is unavoidable since these are fully OA journals. Apply GPOA discounts if eligible and request waivers if needed.

Getting past The Lancet's editorial bar is harder than paying the APC. The Lancet desk-rejects roughly 90% of unsolicited submissions. If you want to check whether your manuscript has the scope and clinical significance The Lancet demands, The Lancet submission readiness check before you submit.

Worth paying if:

• Your funder mandates open access (check Plan S / cOAlition S requirements)
• An institutional Read & Publish agreement covers the fee
• Open access visibility meaningfully benefits your research area
• The APC fits within your grant budget

Consider alternatives if:

• The APC is a personal out-of-pocket expense
• A subscription option or green OA (preprint + embargo) satisfies your funder
• Another OA journal with a lower APC would provide similar visibility